Literature DB >> 35337599

From the Editor's Desk.

Patrick A Flume1.   

Abstract

Entities:  

Year:  2022        PMID: 35337599      PMCID: PMC8938743          DOI: 10.1016/j.jcf.2022.03.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


× No keyword cloud information.
Another year has passed and the pandemic is still upon us. The CF community has demonstrated considerable innovation and resiliency in response to the threat of the novel coronavirus (SARS-CoV-2). I remain highly impressed at how the international CF community came together to share data as we learned about this virus [1]. Clinical care and research were disrupted [2], but we adapted, and those novel approaches to provision of care were shared in our pages. The delivery of care will be forever changed, mostly because of technology but the pandemic was the accelerant. This was described in greater detail in a supplement dedicated to the topic of the future of CF care [3] and we will need to continue to innovate, testing new methods in order to achieve the best for those we serve. Despite the surges of the pandemic, the Journal of Cystic Fibrosis (JCF) and other journals continued to receive a large number of high quality CF-specific manuscripts, demonstrating that scholarly activities would not be denied. We include in this issue a review of CF highlights from the past year [4] to offer but a glimpse of some of the recent major advances in our knowledge. A testament to the high quality of manuscripts submitted to JCF is that we published more articles than any previous year and still had an increase in impact factor. The recently published papers with the greatest number of citations in 2021 are shown in Table 1 . An important observation is that all of these papers are available as Open Access, freely available to all readers. We appreciate that our publisher has worked with countries and institutions to enable authors to publish in this manner, with an increase in Open Access articles by >300 percent. As I have stated before, we do not assess our success by citations alone; our readership includes all members of the multidisciplinary team, persons with CF, and their families. They access JCF through downloads and social media citations, and downloads increased by more than 7% from the previous year.
Table 1

Top Ten Recent Manuscripts Cited in 2021.

TitleType
*Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries [5]Original article
*A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis [6]Original article
*CFTR modulator theratyping: Current status, gaps and future directions [7]Review
*Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease [8]Original article
*Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines [9]Review
*The global impact of SARS-CoV-2 in 181 people with cystic fibrosis [10]Original article
*An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5?years (KLIMB) [11]Original article
*Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis [12]Review
*Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection [13]Original article
*Predictive factors for lumacaftor/ivacaftor clinical response [14]Original article

*Open Access

Top Ten Recent Manuscripts Cited in 2021. *Open Access We remain grateful to the Editorial Board and reviewers who contribute to the peer review processes so vital to JCF. They help us identify and improve the manuscripts that eventually find their way into JCF. We know that the editorial review process places great burden on the editors and reviewers. The editorial board is listed in the masthead of the journal and we include a complete list of all who performed at least one review for JCF in this issue [189--378]. Those individuals who performed at least five reviews are listed in Table 2 , but we especially want to recognize Pierre-Regis Burgel (16), Bradley Quon (15), Jenna Sykes (9), Frank Bodewes (9), and Anne Stephenson (9) as our top five reviewers of 2021.
Table 2

Individuals who performed ≥5 reviews during 2021.

Pierre-Régis Burgel
Bradley Quon
Frank Bodewes
Jenna Sykes
Anne Stephenson
Peter Middleton
Sonya Heltshe
Tanja Gonska
Steven Taylor
Lucy Perrem
Jonathan D. Cogen
Ranjani Somayaji
Kathleen J. Ramos
Clement Ren
Scott C. Bell
Gregory S. Sawicki
Stephanie Van Biervliet
Francois Vermeulen
James F. Chmiel
Isabel Durieu
Stacey L. Martiniano
Edith T. Zemanick
Denis Hadjiliadis
Natalia Cirilli
Alvin Jay Freman
Jill Dorsey
Individuals who performed ≥5 reviews during 2021.
  14 in total

Review 1.  Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.

Authors:  Kathleen J Ramos; Patrick J Smith; Edward F McKone; Joseph M Pilewski; Amy Lucy; Sarah E Hempstead; Erin Tallarico; Albert Faro; Daniel B Rosenbluth; Alice L Gray; Jordan M Dunitz
Journal:  J Cyst Fibros       Date:  2019-03-27       Impact factor: 5.482

2.  Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.

Authors:  Nataliya Volkova; Kristin Moy; Jennifer Evans; Daniel Campbell; Simon Tian; Christopher Simard; Mark Higgins; Michael W Konstan; Gregory S Sawicki; Alexander Elbert; Susan C Charman; Bruce C Marshall; Diana Bilton
Journal:  J Cyst Fibros       Date:  2019-06-10       Impact factor: 5.482

3.  Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis.

Authors:  Andrea Granados; Christine L Chan; Katie Larson Ode; Amir Moheet; Antoinette Moran; Reinhard Holl
Journal:  J Cyst Fibros       Date:  2019-10       Impact factor: 5.482

4.  An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

Authors:  Margaret Rosenfeld; Steve Cunningham; William T Harris; Allen Lapey; Warren E Regelmann; Gregory S Sawicki; Kevin W Southern; Mark Chilvers; Mark Higgins; Simon Tian; Jon Cooke; Jane C Davies
Journal:  J Cyst Fibros       Date:  2019-04-30       Impact factor: 5.482

5.  Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.

Authors:  Siddhartha G Kapnadak; Emily Dimango; Denis Hadjiliadis; Sarah E Hempstead; Erin Tallarico; Joseph M Pilewski; Albert Faro; James Albright; Christian Benden; Shaina Blair; Elisabeth P Dellon; Daniel Gochenour; Peter Michelson; Baharak Moshiree; Isabel Neuringer; Carl Riedy; Teresa Schindler; Lianne G Singer; Dave Young; Lauren Vignola; Joan Zukosky; Richard H Simon
Journal:  J Cyst Fibros       Date:  2020-02-27       Impact factor: 5.482

Review 6.  CFTR modulator theratyping: Current status, gaps and future directions.

Authors:  John Paul Clancy; Calvin U Cotton; Scott H Donaldson; George M Solomon; Donald R VanDevanter; Michael P Boyle; Martina Gentzsch; Jerry A Nick; Beate Illek; John C Wallenburg; Eric J Sorscher; Margarida D Amaral; Jeffrey M Beekman; Anjaparavanda P Naren; Robert J Bridges; Philip J Thomas; Garry Cutting; Steven Rowe; Anthony G Durmowicz; Martin Mense; Kris D Boeck; William Skach; Christopher Penland; Elizabeth Joseloff; Hermann Bihler; John Mahoney; Drucy Borowitz; Katherine L Tuggle
Journal:  J Cyst Fibros       Date:  2018-06-20       Impact factor: 5.482

7.  The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.

Authors:  Elliot McClenaghan; Rebecca Cosgriff; Keith Brownlee; Susannah Ahern; Pierre-Régis Burgel; Catherine A Byrnes; Carla Colombo; Harriet Corvol; Stephanie Y Cheng; Géraldine Daneau; Alexander Elbert; Albert Faro; Christopher H Goss; Vincent Gulmans; Hector Gutierrez; Isabelle de Monestrol; Andreas Jung; Lutz Nährlich Justus; Nataliya Kashirskaya; Bruce C Marshall; Edward McKone; Peter G Middleton; Pedro Mondejar-Lopez; M Dolores Pastor-Vivero; Rita Padoan; Samar Rizvi; Rasa Ruseckaite; Marco Salvatore; Anne Stephenson; Luiz Vicente R da Silva Filho; Joel Melo; Marco Zampoli; Siobhán B Carr
Journal:  J Cyst Fibros       Date:  2020-11-04       Impact factor: 5.482

8.  The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network.

Authors:  Kelsie Pearson; Nicole Mayer-Hamblett; Christopher H Goss; George Z Retsch-Bogart; Jill M VanDalfsen; Patricia Burks; Daniel Rosenbluth; John Paul Clancy; Amy Hoffman; David P Nichols
Journal:  J Cyst Fibros       Date:  2020-12-15       Impact factor: 5.482

9.  Impact of the COVID-19 pandemic: How our response is shaping the future of cystic fibrosis care.

Authors:  Kathryn A Sabadosa; Albert Faro; Eugene C Nelson; Bruce C Marshall
Journal:  J Cyst Fibros       Date:  2021-12       Impact factor: 5.482

Review 10.  A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.

Authors:  H L Barr; T Bihouee; A M Zwitserloot
Journal:  J Cyst Fibros       Date:  2022-03-07       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.